Is hepatic steatosis always present in cirrhosis secondary to metabolic‑dysfunction‑associated fatty liver disease?

No, hepatic steatosis is NOT always present in cirrhosis secondary to MASLD

Steatosis can paradoxically disappear as MASLD progresses to cirrhosis—a phenomenon known as "burned-out NASH." This is a critical clinical pitfall that can lead to misdiagnosis of cirrhosis as "cryptogenic" when it is actually end-stage MASLD 1, 2.

Understanding the Natural History

The progression of MASLD follows this typical pathway 1:

• Simple steatosis → MASH (steatohepatitis with inflammation and ballooning) → Fibrosis → Cirrhosis → HCC

However, as fibrosis advances and the liver architecture becomes increasingly distorted by cirrhosis, the fat content often decreases or disappears entirely. This occurs because:

• Progressive fibrosis replaces functional hepatocytes that would normally accumulate fat
• Advanced cirrhosis disrupts the metabolic machinery required for lipid accumulation
• The regenerative nodules in cirrhotic liver have altered metabolic function

Clinical Implications

The "Cryptogenic Cirrhosis" Problem

Many cases labeled as "cryptogenic cirrhosis" are actually end-stage MASLD where steatosis has burned out 2. This is why you must:

• Look for cardiometabolic risk factors (obesity, type 2 diabetes, hypertension, dyslipidemia) even when steatosis is absent 1
• Consider the patient's metabolic history and past imaging/laboratory data
• Recognize that absence of current steatosis does NOT exclude MASLD as the underlying etiology

Diagnostic Approach in Cirrhosis

When evaluating cirrhosis of unclear etiology 1:

1. Assess for cardiometabolic criteria: The presence of ≥1 of the following strongly suggests MASLD origin even without visible steatosis:

   • BMI ≥25 kg/m² (≥23 kg/m² in Asians)
   • Type 2 diabetes
   • Hypertension
   • Dyslipidemia
   • Waist circumference >94 cm (men) or >80 cm (women) in Caucasians

2. Exclude other causes: Rule out alcohol (>30 g/day men, >20 g/day women), viral hepatitis, autoimmune disease, hemochromatosis, Wilson's disease 1

3. Review historical data: Previous imaging showing steatosis or elevated liver enzymes in the context of metabolic syndrome

Management of MASH-Related Cirrhosis

The 2024 EASL-EASD-EASO guidelines are explicit that no MASH-targeted pharmacotherapy is currently recommended for the cirrhotic stage 1. Management focuses on:

• Metabolic drug adaptations (careful use of GLP-1 agonists, SGLT2 inhibitors with attention to cirrhosis-related contraindications)
• Nutritional counseling to prevent sarcopenia and malnutrition
• Surveillance for portal hypertension (variceal screening, ascites monitoring)
• HCC surveillance every 6 months with ultrasound ± AFP
• Liver transplantation evaluation for decompensated cirrhosis

Key Caveat

While resmetirom is approved for non-cirrhotic MASH with significant fibrosis (stage ≥2), it has no current indication in cirrhotic patients 1. The cirrhotic stage represents a point where anti-fibrotic therapies have not demonstrated benefit, and management shifts to complication prevention and transplant evaluation.

Bottom Line

Do not expect steatosis on imaging or biopsy to diagnose MASLD-related cirrhosis. The diagnosis relies on identifying the cardiometabolic phenotype and excluding alternative etiologies, not on demonstrating current fat accumulation 1, 2. This understanding prevents misclassification and ensures appropriate surveillance and management strategies are implemented.